Xtl Biopharmaceuticals (XTLB) Invested Capital (2011 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Invested Capital of -$68000.0 for Q4 2025, down 103.46% year-on-year from $2.0 million in Q4 2024, and down 103.46% on a QoQ basis from $2.0 million in Q4 2024.
Xtl Biopharmaceuticals (XTLB) Invested Capital (2011 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Invested Capital for 4 consecutive years, with -$68000.0 the latest figure, recorded in Q4 2025.
- Quarterly Invested Capital fell 103.46% year-over-year to -$68000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (down 3.46% YoY) and the FY2025 annual result came in at -$68000.0, down 103.46% from the prior year.
- Invested Capital declined to -$68000.0 in Q4 2025 per XTLB's latest filing, from $2.0 million in the prior quarter.
- Over the last five years, Invested Capital for XTLB reached as high as $2.0 million in Q4 2024 and fell as low as -$68000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 116.14 Mn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | - |
| 10 | Xtl Biopharmaceuticals | 2.50 Bn | 2.50 Bn | - | -68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -68,000.00 |
| Dec 31, 2024 | 1.97 Mn |
| Dec 31, 2017 | 2.67 Mn |
| Dec 31, 2011 | 26,000.00 |